Human milk stimulates prostacyclin production by cultured human vascular endothelial cells. 1991

A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
Children's Hospital, Helsinki, Finland.

Prostacyclin (PGI2) is an antithrombotic and vasodilatory factor, which is produced mainly by the vascular endothelium. Little is known about how this process is regulated. We investigated the effect of human milk on PGI2 synthesis by human vascular endothelial cells by measuring its stable metabolite, 6-keto-prostaglandin F1 alpha, by RIA. Human milk induced dose- and time-dependent stimulation of PGI2 production, whereas cow's milk was ineffective. The lowest concentration of human milk that stimulated the production of PGI2 was 0.1%, and 10% induced a 2.4- to 3.4-fold increase. The effect of human milk was detectable after 2 h and was blocked by inhibitors of transcription, translation, and cyclooxygenase. Boiling abolished the activity, but acetone extraction enhanced it. A 10% concentration of acetone-extracted human milk stimulated the release of endothelial cell PGI2 by 6.6-fold. In human milk samples we found no correlation between the amount of immunoreactive epidermal growth factor (EGF) and the activity stimulating PGI2 synthesis. Furthermore, EGF antibodies did not inhibit the activity. This is the first demonstration that human milk stimulates PGI2 production by endothelial cells. We conclude that human milk is a potent inducer of PGI2 production by human vascular endothelial cells and that the stimulatory activity is not due to EGF.

UI MeSH Term Description Entries
D008895 Milk, Human Milk that is produced by HUMAN MAMMARY GLANDS. Breast Milk,Human Milk,Milk, Breast
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003513 Cycloheximide Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. Actidione,Cicloheximide
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015121 6-Ketoprostaglandin F1 alpha The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. 6-Keto-PGF1 alpha,6-Oxo-PGF1 alpha,6-Oxoprostaglandin F1 alpha,6 Ketoprostaglandin F1 alpha,6 Keto PGF1 alpha,6 Oxo PGF1 alpha,6 Oxoprostaglandin F1 alpha,F1 alpha, 6-Ketoprostaglandin,F1 alpha, 6-Oxoprostaglandin,alpha, 6-Keto-PGF1,alpha, 6-Ketoprostaglandin F1,alpha, 6-Oxo-PGF1,alpha, 6-Oxoprostaglandin F1

Related Publications

A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
January 1989, Advances in prostaglandin, thromboxane, and leukotriene research,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
March 1996, Thrombosis research,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
September 1989, Biochemical and biophysical research communications,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
January 1984, The Journal of clinical investigation,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
June 1990, The Journal of laboratory and clinical medicine,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
January 1988, Arteriosclerosis (Dallas, Tex.),
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
March 1981, The Journal of clinical investigation,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
March 1984, Biochimica et biophysica acta,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
January 1991, Journal of cardiovascular pharmacology,
A Ristimäki, and O Ylikorkala, and K Pesonen, and J Perheentupa, and L Viinikka
February 1987, Transplantation proceedings,
Copied contents to your clipboard!